WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

WuXi XDC Cayman Inc

WuXi XDC is a leading CRDMO focused on the global ADC and broader bioconjugate market and is dedicated to providing integrated services from concept development to commercialization. All services are provided from proximately located, state-of-the-art laboratories and manufacturing facilities, providing high efficiency and significant reduction of development timeline and costs. Our community of over 1000 skilled employees work across a global network to provide an open-access platform with the most comprehensive capabilities and technologies.  WuXi XDC enables its biopharmaceutical partners to innovate, accelerate, and transform the development of the bioconjugate industry, to the benefit of patients worldwide.

	Dec '20	Dec '21	Dec '22	Dec '23
revenue	96.35M -	311.13M 222.91%	990.42M 218.33%	2.12B 114.44%
cost of revenue	88.27M -	197.64M 123.90%	729.34M 269.03%	1.56B 114.48%
gross profit	8.08M -	113.49M 1,304.45%	261.08M 130.04%	559.56M 114.32%
selling and marketing expenses	478K -	2.03M 324.27%	8.77M 332.40%	15.22M 73.57%
general and administrative expenses	9.61M -	27.86M 189.95%	49.21M 76.65%	123.97M 151.91%
selling general and administrative expenses	10.09M -	29.89M 196.31%	57.98M 94.00%	139.19M 140.06%
research and development expenses	4.08M -	13.81M 239.02%	33.84M 144.97%	76.87M 127.13%
other expenses	1.77M -	8.17M 361.43%	6.15M 24.76%	8.85M 43.88%
cost and expenses	62.79M -	240.44M 282.93%	805.38M 234.96%	1.80B 123.19%
operating expenses	-25.48M -	42.80M 267.97%	76.04M 77.65%	233.23M 206.71%
interest expense		493K -	2.92M 491.48%	742K 74.55%
ebitda	46.12M -	96.89M 110.07%	272.90M 181.67%	392.33M 43.76%
operating income	32.66M -	77.90M 138.57%	242.09M 210.75%	332.82M 37.48%
depreciation and amortization	13.46M -	18.98M 40.97%	30.81M 62.33%	167.90K 99.46%
total other income expenses net	-289K -	-11.05M 3,723.88%	-46.28M 318.83%	26.79M 157.89%
income before tax	32.37M -	66.85M 106.55%	195.80M 192.88%	359.61M 83.66%
income tax expense	6.07M -	11.92M 96.52%	40.07M 236.07%	76.07M 89.85%
net income	26.30M -	54.93M 108.87%	155.73M 183.51%	283.54M 82.07%
weighted average shs out	1.18B -	1.18B 0%	1.18B 0%	1.02B 13.19%
weighted average shs out dil	1.18B -	1.18B 0%	1.18B 0%	1.08B 8.53%
eps	0.02 -	0.05 108.97%	0.13 178.97%	0.28 115.38%
epsdiluted	0.02 -	0.05 108.97%	0.13 178.97%	0.26 100%

2268

COM:WUXIXDC

WuxiXDC

Last Close

26.00

22/11 05:05

Market Cap

19.17B

Beta: -

Volume Today

1.06M

Avg: -

Preview